EGFR and non-small cell lung carcinoma: In the recently updated FLAURA phase 3 study of 556 previously untreated NSCLC patients harboring EGFR exon 19 deletion or L858R mutation, osimertinib showed superiority over the standard EGFR-TKIs gefitinib or erlotinib in median OS (38.6 vs 31.8 months) and a similar safety profile (adverse events of grade 3 or higher 42% vs 47%).[9] Subsequently, it was also approved as a first-line treatment for metastatic NSCLC patients harboring EGFR exon 19 deletions or L858R mutations.